title: Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report.
abstract: BACKGROUND
  A detailed description is given of a case we encountered in which unexpectedly marked weight gain occurred following a treatment switch from a GLP-1 receptor agonist to an SGLT-2 inhibitor
  
  
  METHODS
  The patient, a 44-year-old man with type 2 diabetes mellitus, had gained about 10 kg in weight in the previous year. Therefore, metformin was replaced with liraglutide to obtain reduction of body weight. Although the patient lost about 8 kg (7%), during the 18-month period on the medication, the weight loss stabilized; therefore, the treatment was again switched to tofogliflozin to obtain further reduction of body weight. However, the patient reported increasing hunger and an exaggerated appetite from week 3 onward after the start of tofogliflozin, and gained about 9 kg in weight within 2 weeks, associated with a tendency towards increased HbA1c; therefore, tofogliflozin was discontinued. Immediate reinstitution of liraglutide resulted in reduction of the increased appetite, weight, and HbA1c level.
  
  
  CONCLUSIONS
  Caution should be exercised against hyperphagia and weight gain due to hunger that may occur following discontinuation of a GLP-1 receptor agonist and/or initiation of an SGLT-2 inhibitor.
authors.affiliation: Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
authors.forename: Hiromi
authors.initials: H
authors.lastname: Hamamoto
authors.affiliation: Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Noda
mesh_terms: D000328:Adult; D001559:Benzhydryl Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006963:Hyperphagia / Q000139:chemically induced* / Q000378:metabolism; D008297:Male; D051269:Sodium-Glucose Transporter 1 / Q000037:antagonists & inhibitors*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; C495674:SLC5A1 protein, human; D051269:Sodium-Glucose Transporter 1; C575086:6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol